Search Results

Rivus Pharmaceuticals today announced publication of the rationale and design of the company’s Phase 2a HuMAIN trial in the European Journal of Heart Failure.

Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.

Rivus Pharmaceuticals Inc. today announced key clinical and corporate updates.

Rivus Pharmaceuticals Inc. today announced the completion of enrollment in its Phase 2a HuMAIN trial of HU6, an investigational controlled metabolic accelerator (CMA), in patients with the obese phenotype of heart failure with preserved ejection fraction (HFpEF).

Rivus Pharmaceuticals Inc. today announced the appointment of Jayson Dallas, M.D., executive chairman for Rivus Pharmaceuticals, as Chief Executive Officer.

Rivus Pharmaceuticals Inc. today announced publication in The Lancet Gastroenterology & Hepatology of the results of a Phase 2a metabolic study of HU6, an investigational first-in-class controlled metabolic accelerator (CMA), in patients with nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD), and a high body mass index (BMI).

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

Rivus Pharmaceuticals Inc. today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital.